Shareholders in Innospec Inc. (NASDAQ:IOSP) had a terrible week, as shares crashed 20% to US$80.65 in the week since its latest third-quarter results. Innospec reported US$474m in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$1.29 beat expectations, being 3.2% higher than what the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Taking into account the latest results, the current consensus from Innospec's three analysts is for revenues of US$2.02b in 2027. This would reflect a credible 7.6% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to rise 3.9% to US$5.92. In the lead-up to this report, the analysts had been modelling revenues of US$2.02b and earnings per share (EPS) of US$5.95 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
Check out our latest analysis for Innospec
The analysts reconfirmed their price target of US$101, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Innospec analyst has a price target of US$110 per share, while the most pessimistic values it at US$93.00. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Innospec's growth to accelerate, with the forecast 6.0% annualised growth to the end of 2027 ranking favourably alongside historical growth of 2.0% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 4.7% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Innospec is expected to grow much faster than its industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Innospec going out to 2027, and you can see them free on our platform here..
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Innospec that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.